Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment

References

• Cantón R, Cobos N, de Gracia J, Baquero F, Honorato J, Gartner S, . Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect 2005;11: 690–703.
   PubMed Web of Science ®Google Scholar
• Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996;60:539–74.
   PubMedGoogle Scholar
• Taccetti G, Campana S, Neri AS, Boni V, Festini F. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis. J Chemother 2008;20:166–9.
   PubMed Web of Science ®Google Scholar
• Govan JR. Insights into cystic fibrosis microbiology from the European tobramycin trial in cystic fibrosis. J Cyst Fibros 2002;1:203–8.
   PubMedGoogle Scholar
• Wood DM, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2006;(1):CD004197.
   Google Scholar
• Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23:330–5.
   PubMed Web of Science ®Google Scholar
• Doring G, Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004;3:67–91.
   PubMedGoogle Scholar
• Ratjen F, Doring G. Cystic fibrosis. Lancet 2003;361: 681–9.
   PubMed Web of Science ®Google Scholar
• Moskowitz SM, Silva SJ, Mayer-Hamblett N, Pasta DJ, Mink DR, Mabie JA, . Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr Pulmonol 2008;43:874–81.
   PubMed Web of Science ®Google Scholar
• Pitt TL, Sparrow M, Warner M, Stefanidou M. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 2003;58:794–6.
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, . Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23–30.
   PubMed Web of Science ®Google Scholar
• Jensen T, Pedersen SS, Garne S, Heilmann C, Hoiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987;19:831–8.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement. M100-S20, Vol. 30. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.
   Google Scholar
• Mahenthiralingam E, Campbell ME, Foster J, Lam JS, Speert DP. Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J Clin Microbiol 1996;34: 1129–35.
   PubMed Web of Science ®Google Scholar
• UK Cystic Fibrosis Trust Antibiotic Working Group. Antibiotic treatment for cystic fibrosis. 3rd Bromley, Kent: Cystic Fibrosis Trust; 2009. Available at: http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/Antibiotic_treatment_for_Cystic_Fibrosis.pdf (accessed July 2010).
   Google Scholar
• Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, . Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802–8.
   PubMed Web of Science ®Google Scholar
• Saiman L, Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol 2003; 24:S6–52.
   PubMed Web of Science ®Google Scholar
• Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, . Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999;179:1190–6.
   PubMed Web of Science ®Google Scholar
• Heijerman H, Westerman E, Conway S, Touw D, Doring G. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2009;8:295–315.
   PubMed Web of Science ®Google Scholar
• Morosini MI, Garcia-Castillo M, Loza E, Perez-Vazquez M, Baquero F, Canton R. Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips. J Clin Microbiol 2005;43:4480–5.
   PubMed Web of Science ®Google Scholar
• Johansen HK, Moskowitz SM, Ciofu O, Pressler T, Hoiby N. Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J Cyst Fibros 2008;7:391–7.
   PubMed Web of Science ®Google Scholar